Melanoma Brain Metastases: Local Therapies, Targeted Therapies, Immune Checkpoint Inhibitors and Their Combinations—Chances and Challenges

Recent phase II trials have shown that BRAF/MEK inhibitors and immune checkpoint inhibitors are active in patients with melanoma brain metastases (MBM), reporting intracranial disease control rates of 50–75%. Furthermore, retrospective analyses suggest that combining stereotactic radiosurgery with i...

Descripción completa

Detalles Bibliográficos
Autores principales: Kuske, Marvin, Rauschenberg, Ricarda, Garzarolli, Marlene, Meredyth-Stewart, Michelle, Beissert, Stefan, Troost, Esther G. C., Glitza, Oliva Isabella Claudia, Meier, Friedegund
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2018
Materias:
Review Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6061393/
https://www.ncbi.nlm.nih.gov/pubmed/29417399
http://dx.doi.org/10.1007/s40257-018-0346-9

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6061393/
https://www.ncbi.nlm.nih.gov/pubmed/29417399
http://dx.doi.org/10.1007/s40257-018-0346-9

Ejemplares similares